

PAVE PATIENT-DRIVEN
VALUES *in* HEALTHCARE
EVALUATION



Patient-Driven Values in Healthcare Evaluation (PAVE) is a unique collaboration between the University of Maryland School of Pharmacy, the National Health Council, patient community leaders, and payer and industry leaders. The organization is dedicated to developing and advancing new methods to incorporate the patient perspective into value assessment and value-based decision-making. Through this initiative, PAVE is building a diverse and extensive network of partners to build technical expertise in patient-centered health outcomes research, education, and dissemination. PAVE is a recipient of the PhRMA Foundation's Value Assessment Initiative Centers of Excellence Award.

Overview

Patient engagement and perspective is critical to any discussion of value, yet unconventional assessment models often fail to fully capture the patient perspective. It is important for the field of value assessment to evolve to more patient-centric models. PAVE is at the forefront of this movement, developing approaches to value assessment that:

- Solicit meaningful input from patients
- Ensure transparency in methods and decisions
- Develop creative solutions to meet the needs of all health care decision makers

To achieve patient-driven value assessment, it is important to work with patient partners from start to finish. This involves calculating multiple value metrics from different perspectives, and highlighting differences in preferences for treatment and their effects.

Ongoing Activities

- Engage diverse patient communities to identify costs and benefits of treatments that are most important to patients
- Measure patient values and preferences for health-related benefits and risks to incorporate into economic evaluation of treatments
- Test different methodological approaches for patient-driven value assessment in health care interventions and services for individuals
- Perform patient-driven cost-effectiveness analyses using patient-informed value elements
- Educate the patient and research communities on patient-driven value assessment
- Partner with Hispanic community groups to understand patient values that are under-represented in health care evaluation and decision-making

Website

www.pharmacy.umaryland.edu/centers/patient-driven-values-healthcare-evaluation-pave/

Key Staff

Susan dosReis, PhD

Director

sdosreis@rx.umaryland.edu

Julia Slejko, PhD

Research Core Lead

jslejko@rx.umaryland.edu

Wendy Camelo Castillo, MD, MSc, PhD

Hispanic Patient Engagement Core Lead

wcastillo@rx.umaryland.edu

Joey Mattingly, PhD, PharmD, MBA

Director of Operations

jmattingly@rx.umaryland.edu

C. Daniel Mullins, PhD

Patient Engagement Core Lead

dmullins@rx.umaryland.edu

Eleanor Perfetto, PhD, MS

Education Core Lead

eperfetto@rx.umaryland.edu

Videos & Infographics

Video: PhRMA Foundation Centers of Excellence: [Spotlight on PAVE](#)

Video: [What You Need To Know About Hepatitis C](#)

Video: [More Than A Virus: The Impact of Hepatitis C](#)

Infographic: [Patient-Centered Value Assessment: Hepatitis C \(HCV\) treatment](#)

Original Research

Slejko JF, Hong YD, Sullivan JL, Reed RM, dosReis S. [Prioritization and Refinement of Patient-Informed Value Elements as Attributes for Chronic Obstructive Pulmonary Disease Treatment Preferences](#). *The Patient*. Online ahead of print. February 8, 2021. DOI: 10.1007/s40271-021-00495-2

dosReis S, Butler B, Caicedo J, Kennedy A, Hong YD, Zhang C, Slejko JF. [Stakeholder-Engaged Derivation of Patient-Informed Value Elements](#). *The Patient*. Online ahead of print. July 17, 2020. DOI: 10.1007/s40271-020-00433-8

Mattingly II TJ, Love BL. [Changes in Cost-effectiveness for Chronic Hepatitis C Virus Pharmacotherapy: The Case for Continuous Cost-effectiveness Analyses](#). *Journal of Managed Care & Specialty Pharmacy*. 2020;26(7):879-886. DOI: 10.18553/jmcp.2020.26.7.879.

Mattingly, T.J., Slejko JF, Onukwugha E, Perfetto EM, Kottlil S, Mullins CD. [Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis](#). *PharmacoEconomics*. 2019. 38(2):233-242. DOI: 10.1007/s40273-019-00864-8

Mattingly II TJ, Slejko JF, Perfetto EM, Kottlil S, Mullins CD. [What Matters Most for Treatment Decisions in Hepatitis C: Effectiveness, Costs, and Altruism](#). *The Patient*. 2019; 12:631-638. DOI: 10.1007/s40271-019-00378-7

Reviews and Commentary

Mattingly II TJ. [PCORI's Expanded Mandate Creates New Opportunities for Value Assessment Research](#). *American Journal of Accountable Care*. July 29, 2021. 2021;9(3):19-21. <https://doi.org/10.37765/ajac.2021.88720>

McQueen RB, Slejko JF. [Toward Modified Impact Inventory Tables to Facilitate Patient-Centered Value Assessment](#). *PharmacoEconomics*. Online ahead of print. March 24, 2021. DOI:/10.1007/s40273-021-01017-6.

Desai B, Mattingly II TJ, van den Broek R, Pham N, Frailer M, Yang J, Perfetto EM. [Peer Review and Transparency in Evidence-Source Selection in Value and Health Technology Assessment](#). *Value in Health*. Online ahead of print, April 6, 2020. DOI: 10.1016/j.jval.2020.01.014.

Mattingly II TJ, Love BL, Khokhar B. [Real World Cost-of-Illness Evidence in Hepatitis C Virus: A Systematic Review](#). *PharmacoEconomics*. Online ahead of print June 13, 2020. DOI: 10.1007/s40273-020-00933-3.

Mattingly II TJ. [The Economics of Drug Allergy](#). *Current Opinion in Allergy & Clinical Immunology*. Online ahead of print May 20, 2020. DOI: 10.1097/ACI.0000000000000651.

Mattingly II TJ, Shere-Wolfe K. [Clinical and Economic Outcomes Avaluated in Lyme Disease: A Systematic Review](#). *Parasites & Vectors*. 2020;13:34. DOI: 0.1186/s13071-020-04214-y.

Harrington RL, Hanna ML, Oehrlein EM, et al. [Defining Patient Engagement in Research: Results of a Systematic Review and Analysis: Report of the ISPOR Patient-Centered Special Interest Group](#). *Value Health*. 2020;23(6):677-688. DOI:10.1016/j.jval.2020.01.019.

Mattingly II TJ. [Elimination of Hepatitis C Virus Infection in Canada is Achievable, But is the Rest of the World Ready to Join in This Effort?](#) *JAMA Network Open*. 2020;3(5):e204355. DOI:10.1001/jamanetworkopen.2020.

Mattingly II TJ, Heil EL. [The Economics of Penicillin Allergy Testing: Still Scratching the Value Surface](#). *Clinical Infectious Diseases*. Online ahead of print, February 28, 2020.

Slejko, J.F., Mattingly, T.J., Mullins C.D., Perfetto E.M., dosReis, S. [The Future of Patient-Driven Healthcare Evaluation: The Patient-Informed Reference Case](#). *Value in Health*. 2019 May;22(5):545-548. DOI:: 10.1016/j.jval.2019.02.003.

Op-eds, Editorials & Blog Posts

dosReis, S. [The Patient Perspective Approach Should Guide Value Assessments of COVID-19 Vaccines](#). *Medium*. May 18, 2021

Mattingly, T.J., [Centering the Patient Perspective in Hepatitis C Treatment Evaluation](#). *Voices in Value*. May 14, 2021

Camelo Castillo, W. [Racial and Ethnic Disparities in Health Care are Found in the Missing Patient Voice](#). *Medium*. November 10, 2020

Mattingly, T.J., McQueen R.B. [Using PCORI to Advance Patient-Centered Values](#). *Fierce Healthcare*. November 6, 2019

dosReis, S. [Making the Patient Voice Matter In Value Assessment](#). *Managed Care Magazine*. September 3, 2019.

Mattingly, T.J., Slejko, J.F., Perfetto, E.M., dosReis, S. [Putting Our Guard Down: Engaging Multiple Stakeholders to Define Value in Healthcare](#). *Health Affairs Blog*. January 28, 2019

Presentations

Podium Presentations:

Eliciting Value Elements for a Patient-Driven Value Assessment. Hong YD, Zhang C, Slejko JF, dosReis S. *Value in Health*. May 2019;22(Suppl. 2):S37.

Poster Presentations:

A Patient-Informed Approach to Develop a Discrete Choice Experiment for COPD Treatment. Slejko JF, Hong YD, Bozzi LM, dosReis S. Virtual ISPOR 2020. May 18-22, 2020. *Value in Health*. 2020;23:S360.

Aligning COPD Outcomes with Patient-Informed Value Element Domains for Use in Economic Evaluations. Slejko JF, Gray C, Hong YD, Rueda JD, Zhang C, dosReis S. *Value in Health*. May 2019;22(Suppl. 2):S351.

Identifying COPD Patient-Informed Value Elements in Economic Evaluations: A Systematic Review. Gray C, Slejko JF. *Value in Health*. May 2019;22(Suppl. 2):S361.

Workshops/Issue Panel:

An Analytic Approach to Incorporating Patient Preferences into Value Elements for Economic Evaluation. dosReis S, Slejko JF, Lakdawalla DN, Willke RJ. ISPOR 2019 Workshop. May 2019.

Invited Seminars

Susan dosReis, PhD, UMB, Jennifer Bright, MPA, IVI, Yvette Venable, ICER. Value Assessment and Women. Society for Women's Health Research. *Virtual Policy Council Meeting*. June 3, 2020.

Julia Slejko, PhD (PAVE), Jamie Sullivan (COPD Foundation).

Moderator: Eleanor Perfetto, PhD (PAVE)

"Partners' Perspectives on the Value of a Patient-Researcher Partnership".

National Health Council 2019 Science of Patient Engagement Symposium.

October 28-29, 2019. Washington, D.C.

Lisa Bo Feng, DrPH (Cystic Fibrosis Foundation), Susan dosReis, PhD (PAVE), Josh Seidman, PhD (Avalere Health), David Steinhorn, MD (Children's National Medical Center).

Moderator: Jennifer Bright, MPA (Momentum Health Strategies).

"Navigating the Frontiers of Innovation and Value: The Value of the Patients Voice".

Alliance for Health Policy 2019 Solving Health Signature Series.

November 6, 2019, Washington, D.C.

Susan dosReis, PhD (PAVE), George Miller, PhD (RC-HCVA), Jon Campbell, PhD (pValue), Peter Neumann, ScD (CEVA).

Moderator: Sachin Kamal-Bahl, PhD (COVIA Health Solutions).

“Grant Recipients Highlight New Approaches to Value Assessment”.

The Next Generation of Value Assessment: Including the Patients Voice Series by PhRMA Foundation & National Health Council.

November 12, 2019, Washington, D.C.

Julia Slejko, PhD (PAVE)

“Value Assessments and the Role of the Patient Voice”.

COPD Foundation IMPACT COPD Workshop

June 18, 2019, Washington, D.C.